key: cord-1051206-8m6793vd authors: Xiong, Yujuan; Li, Zhen-Zhen; Zhuang, Qi-Zhen; Chao, Yan; Li, Fei; Ge, Yi-Yuan; Wang, Yi; Ke, Pei-Feng; Huang, Xian-Zhang title: Comparative performance of four nucleic acid amplification tests for SARS-CoV-2 virus date: 2020-03-29 journal: bioRxiv DOI: 10.1101/2020.03.26.010975 sha: 2b3410564f2be7051199e6996bb69efc65cced47 doc_id: 1051206 cord_uid: 8m6793vd Coronavirus disease 2019 (COVID-19) can be screened and diagnosed through the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time reverse transcription polymerase chain reaction. SARS-CoV-2 nucleic acid amplification tests (NAATs) have been rapidly developed and quickly applied to clinical testing during the pandemic. However, studies evaluating the performance of these NAAT assays are limited. We evaluated the performance of four NAATs, which were marked by the Conformité Européenne and widely used in China during the pandemic. Results showed that the analytical sensitivity of the four assays was significantly lower than that claimed by the NAAT manufacturers. The limit of detection (LOD) of Daan, Sansure, and Hybribio NAATs was 3000 copies/mL, whereas the LOD of Bioperfectus NAATs was 4000 copies/mL. The results of the consistency test using 46 samples showed that Daan, Sansure, and Hybribio NAATs could detect the samples with a specificity of 100% (30/30) and a sensitivity of 100% (16 /16), whereas Bioperfectus NAAT detected the samples with a specificity of 100% (30/30) and a sensitivity 81.25% (13/16). The sensitivity of Bioperfectus NAAT was lower than that of the three other NAATs; this finding was consistent with the result that Bioperfectus NAAT had a higher LOD than the three other kinds of NAATs. The four above mentioned reagents presented high specificity; however, for the detection of the samples with low virus concentration, Bioperfectus reagent had the risk of missing detection. Therefore, the LOD should be considered in the selection of SARS-CoV-2 NAATs. amplification tests (NAATs) have been rapidly developed and quickly applied to 23 clinical testing during the pandemic. However, studies evaluating the performance of 24 these NAAT assays are limited. We evaluated the performance of four NAATs, which 25 were marked by the Conformité Européenne and widely used in China during the 26 pandemic. Results showed that the analytical sensitivity of the four assays was 27 significantly lower than that claimed by the NAAT manufacturers. The limit of 28 detection (LOD) of Daan, Sansure, and Hybribio NAATs was 3000 copies/mL, 29 whereas the LOD of Bioperfectus NAATs was 4000 copies/mL. The results of the 30 consistency test using 46 samples showed that Daan, Sansure, and Hybribio NAATs 31 could detect the samples with a specificity of 100% (30/30) and a sensitivity of 100% 32 (16 /16), whereas Bioperfectus NAAT detected the samples with a specificity of 100% 33 (30/30) and a sensitivity 81.25% (13/16). The sensitivity of Bioperfectus NAAT was 34 lower than that of the three other NAATs; this finding was consistent with the result 35 that Bioperfectus NAAT had a higher LOD than the three other kinds of NAATs. The 36 four above mentioned reagents presented high specificity; however, for the detection 37 of the samples with low virus concentration, Bioperfectus reagent had the risk of 38 missing detection. Therefore, the LOD should be considered in the selection of Introduction 46 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly 47 since its recent identification in patients with severe pneumonia in Wuhan, China(1-3). 48 To date, SARS-CoV-2 has affected more than 372,000 patients worldwide and 49 resulted in more than 16,000 deaths (as of March 24, 2020)(4). The World Health 50 Organization (WHO) has declared the Chinese outbreak of coronavirus disease 2019 51 to be a Public Health Emergency of International Concern and stated 52 that the spread of COVID-19 may be interrupted by early detection, isolation, prompt 53 treatment, and the implementation of a robust system(4, 5). On March 11, at a regular 54 press conference in Geneva, WHO Director-General Tan Desai said that the 55 COVID-19 epidemic can be called a pandemic in terms of its characteristics. Unfortunately, no drug or vaccine has yet been approved to treat human coronaviruses, 57 and new interventions are likely to require months to years to develop(6). Therefore, 58 early diagnosis of SARS-CoV-2 infection is important to distinguish it from 59 asymptomatic, healthy, and other pathogenic infections and to ensure timely isolation 60 of the infected patients. Although real-time RT-PCR assay is a highly sensitive technique, false negative 72 results have still been reported in some COVID-19 patients. These results may occur 73 due to insufficient organisms in the specimen resulting from improper collection, 74 transportation, storage, and handling, as well as laboratory test conditions and 75 personnel operation (11) (12) (13) . Moreover, the quality of the examined regents is related 76 closely to the PCR results for SARS-CoV-2. In response to this outbreak, a number of 77 nucleic acid amplification tests (NAATs) for SARS-CoV-2 were rapidly developed in 78 China and quickly applied to clinical testing. To date, no quality evaluation of 79 SARS-CoV-2 NAATs has been reported. The purpose of this study was to comprehensively evaluate the performance of four 82 SARS-CoV-2 NAATs, which were Conformité Européenne (CE) marked and widely 83 used. The results of this study will be helpful for laboratorians to select the 84 appropriate assay for detecting SARS-CoV-2. Serial dilutions were made with a known concentration of the target substance in the 136 analytical range of the expected limit of detection (LOD) and tested in replicates of 20. All panel members were prepared at the same time, aliquoted into individual tubes for 138 each concentration and each assay, stored frozen, and thawed on the day of testing. When 19 or all 20 replicates were positive, the concentration was temporarily defined 140 as LOD, followed by 20 replicates per day for two consecutive days, yielding a total 141 of 60 results. If more than 95% of the results were positive, the concentration was Accuracy. Ten positive reference materials and two negative reference materials from 155 the performance verification reference material kit were used to evaluate accuracy. Analytical interferences. To investigate the analytical interferences, three 168 interference reference materials from the performance verification reference material 169 kit were used, including 6 g/dL hemoglobin, 30 g/dL albumin, and the mix of 100 170 µg/mL ribavirin and 100 µg/mL azithromycin. All tests were repeated three times. all four systems were less than 4%, and the total CVs were less than 5% (Table 2) . Analytical interferences. An assessment of interferences is shown in Table 3 . The 232 bias of Ct value for the N gene and ORF1ab gene on all four systems was less than 233 8.5% at the following interfering substance concentrations tested: 6 g/dL hemoglobin, 234 30 g/dL albumin, 100 µg/mL ribavirin, and 100 µg/mL azithromycin. Comparison of the four NAATs. We defined consistency as two or more tests that In the present study, we further compared four NAATs for the detection of Obtaining high-quality viral RNA from original clinical samples is crucial to ensure 296 the accuracy of the detection results by NAATs. Therefore, the poor quality of 297 extraction reagents and the unoptimized extraction process of viral RNA would affect 298 the detection results. In this study, the performance of NAATs was evaluated by using 299 the same viral RNA samples. Therefore, the difference in the experimental results 300 only reflected the difference in the performance of nucleic acid amplification for 301 NAATs but not the diversity in the performance of the whole SARS-CoV-2 detection 302 system, which usually includes the nucleic acid extraction system. In summary, the four SARS-CoV-2 NAATs commonly used with commercial assays 313 showed good reliability, but the actual LOD was significantly higher than the declared 314 LOD. The analytic sensitivity of Daan, Sansure, and Hybribio NAATs was slightly 315 higher than that of Bioperfectus NAAT. China Novel Coronavirus I, Research T. 2020. A Novel 325 Coronavirus from Patients with Pneumonia in China A novel coronavirus outbreak of global health 327 concern Early Transmission 332 Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Novel Coronavirus(2019-nCoV): Situation Report Clinical management of severe acute respiratory infection 336 when novel coronavirus (2019-nCoV) infection is suspected: interim guidance Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic 342 Review Emergence of a Novel Coronavirus Disease (COVID-19) and the 344 Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public 345 Health Agencies, and Industry Is Essential to Control the Outbreak Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing 349 an Outbreak of Pneumonia Improved molecular diagnosis of 352 COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse 353 transcription-polymerase chain reaction assay validated in vitro and with clinical specimens The transmission and diagnosis of 2019 novel coronavirus infection 356 disease (COVID-19): A Chinese perspective SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 359 Infected Patients Comparison of different samples for 2019 novel coronavirus detection by 362 nucleic acid amplification tests Comparison of the AmpliVue, BD Max System, and 364 illumigene Molecular Assays for Detection of Group B Streptococcus in Antenatal Screening 365 Specimens National Health Commission. The guidelines for the diagnosis and treatment of severe acute 367 respiratory syndrome coronavirus 2(SARS-CoV-2)infection The authors would like to thank the Chinese Academy of Metrology, Sansure, 319 Bioperfectus, and Hybribio for supplying the test kits.